New Option Option in Pharmacological Treatment of Uterine Fibrinoids: Selective Progesterone Receptor Modulators

Abstract

The most frequently identified benign tumor in women is represented by the uterine fibroids with various symptoms: metrorrhagia, dysmenorrhea, anemia, pelvic pain. Nowadays because none of the approved medical treatments has proven able to completely eliminate uterine fibroids, surgery represents the main treatment strategy. Due to its contribution in the growth of leiomyomas, progesterone plays an important role. The purpose of this study is to review the data available regarding the safety and effectiveness of the selective progesterone receptor modulators (SPRM) used in uterine fibroids treatment. A review of the literature was performed between September 2015- January 2016 aiming to identify the studies mentioning the use and effectiveness of SPRM in uterine fibroids treatment. A total of 37 studies were identified, 9 matching inclusion criteria. All studies included in our research gave information regarding drug safety, potential benefits, metrorrhagia control and mass reduction of the fibroid. The results were that the pain and life quality showed marked improvement even after therapy interruption. Among all SPRM available (UPA- ulipristal acetate, asoprinisil, telapristone acetate and GnRh agonists), the treatment with UPA revealed a fast metrorrhagia control and a reduction in the mass dimension, both effects persist even after cessation of medication.